Credit Suisse Health Care Conference

Doug Manion Senior Vice President, Development Virology, Neuroscience and Japan

November 14, 2012

1 Forward-Looking Information

During this meeting, we will make statements about the Company’s future plans and prospects that constitute forward- looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated as a result of various important factors, including those discussed in the company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations.

In addition, any forward-looking statements represent our estimates only as of today and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change.

NOT FOR PRODUCT PROMOTIONAL USE 2 Data as of June 30, 2012 NME Development Portfolio Full Marketed Product Exploratory Development * Development ^ Development †

CCR1 Anti-Fucosyl GM1 PEG-FGF21 NS5B Non Nuc TM Antagonists Brivanib YERVOY NULOJIX ® 11βHSD NS5B Primer Grip JAK2 Inhibitor LXR Modulators TM Inhibitor Inhibitor SPRYCEL® ELIQUIS *** Necitumumab IGF-1R Antidiabetic NS5B Site 1 PCSK9 Adnectin Antagonist Peptide** Inhibitor ERBITUX® BARACLUDE® CCR2 / 5 a-7 Nicotinic Elotuzumab SMO Antagonist IL-23 Adnectin ONGLYZA® / Antagonists Agonist REYATAZ® KOMBIGLYZETM XR

IL-21 Anti-IL23 IKur Antagonists Ab Modulator Dapagliflozin ® ® SUSTIVA / SYMLIN ** ATRIPLA® Factor XIa Triple Reuptake Anti-KIR Anti-CD40L Parenteral Inhibitor ® Metreleptin** BYETTA / ABILIFY® BYDUREONTM** Urelumab Microtubule IKACh Inhibitor (Anti-CD137) Anti- CD40 Stabilizer Daclatasvir ORENCIA® Avagacestat (NS5A Inhibitor) HIV Attachment Notch Inhibitor Anti-CD28 (Gamma Secretase Inhibitor Inhibitor) Asunaprevir Anti-PD1 Anti-IL31 NRT Inhibitor GABA/Nicotinic (NS3 Inhibitor) Modulator

Anti-CXCR4 HIV Maturation Peginterferon LPA1 Antagonist Inhibitor CGRP Antagonist lambda-1a

Anti-LAG3 Anti-IL6 Anti-PD-L1 * Post discovery through Phase II NS5A Second GPR119 Agonists Anti-IP10 Generation ^ Registrational program † Approved in at least one major market

INX-189 was removed on August 23, 2012 ** Amylin compounds added on August 9, 2012 NS ONC MET IMM CV VIR *** ELIQUIS is approved for VTE Prevention in the EU 3 BMS Commitment to HCV

 Discontinuation of BMS-986094 disappointing

 We believe we are well positioned with a broad portfolio designed to address needs across a number of patient populations and geographies

 We continue to explore strategic partnerships to complement our internal portfolio

NOT FOR PRODUCT PROMOTIONAL USE 4 BMS Strategy: A Multipronged Approach to Optimize Opportunity

Current Standard of Care Potential Future Treatment Options

Direct Acting Antiviral(s) +/- Pegylated -a + Novel Lambda Interferon Ribavirin +/- + Direct Acting Antiviral(s) +/-Ribavirin Telaprevir or Boceprevir Pegylated Interferon-a + Ribavirin + Direct Acting Antiviral(s)

5 Broad Late-Stage HCV Portfolio Provides Multiple Approaches to Possible New Treatments

Asset Description

Daclatasvir (DCV) First-in-class NS5A inhibitor

Asunaprevir (ASV) Potent NS3 Inhibitor Peginterferon Novel Type III interferon Lambda from ZymoGenetics Potent Non-Nucleos(t)ide BMS-791325 NS5B Inhibitor Leveraging key partnerships to complement our internal portfolio

NOT FOR PRODUCT PROMOTIONAL USE 6 Key HCV Development Programs: Using Different Combinations for Different Patient Segments

Daclatasvir  Combinations with PEG-IFNα/R (DCV) – Ph III studies ongoing

Asunaprevir  Dual therapy (DCV + ASV) (ASV) – Ph III study ongoing in Japan – Ph III initiated in US, EU

 Quad therapy (DCV + ASV + PEG-IFNα/R) to start in 2012 Peginterferon  Ph III studies in HCV begun Lambda  Ph II ongoing in hepatitis B

NS5B Non-  Triple therapy (DCV + ASV +’325 ) Nuc Inhibitor – Ph II study expanded to enable Phase III start in first half 2014

PEG -IFNα/R =Pegylated-Interferon Alfa + ribavirin

NOT FOR PRODUCT PROMOTIONAL USE 7 All-Oral Regimen for GT1b: Dual Therapy of Daclatasvir + Asunaprevir

 Phase II data showed high rates of sustained virologic response in GT1b Japanese patients (null responders or ineligible/intolerant to PEG -IFNα/R)

 Phase III registrational study in Japanese GT1b null responders and ineligible/intolerant patients – Data expected in mid-2013 with potential filing at the end of 2013 – Potential for first all-oral regimen to market in Japan

 Exploring options to augment this program globally and to include additional studies in naïve GT1b patients

PEG -IFNα/R =Pegylated-Interferon Alfa + ribavirin NOT FOR PRODUCT PROMOTIONAL USE 8 Triple Therapy: Daclatasvir + Asunaprevir + BMS-791325 – Results of Phase II 12 Week Therapy

 First company to study triple DAA regimen that is interferon-, ritonavir-, and ribavirin-free

 94% (15/16) subjects achieved SVR4 – 12/12 GT1a subjects achieved SVR4 – 1 Subject (GT1b) lost to follow-up (3/3 observed achieved SVR4) – No viral breakthrough in either group – No viral relapse to date

 Safety results consistent with favorable risk/benefit profile

 Ph II ongoing; Ph III registrational program planned for 1H 2014

NOT FOR PRODUCT PROMOTIONAL USE 9 HCV RNA Endpoints Modified Intention-to-Treat Analysis 24-Week Treatment 12-Week Treatment Group 1, N = 16 Group 2, N = 16

HCV RNA < LLOQTD or TND HCV RNA < LLOQTD or TND Missing data Missing data 100 94 94a 94 100 88 100 94 94 % < LLOQ 100 100 TD or TND 90 90 80 80 70 70 60 60 50 50 40 40

endpoint (%) endpoint 30 30

Patients achieving Patients 20 20 10 10 0 0 b b 4 12 EOT SVR4 4 12 EOT SVR4 SVR12 Study Week a Includes 1 patient with HCV RNA 118 IU/mL at last on-treatment visit but < LLOQTND 2 and 4 weeks posttreatment (SVR4). b EOT, end of treatment; includes patients who discontinued prior to the protocol-defined last treatment visit.

< LLOQTD or TND, HCV RNA below assay lower limit of quantitation (25 IU/mL) and target detected (LLOQTD) or target not detected (LLOQTND); HCV RNA < LOD ≈ 10 IU/mL, previously reported as HCV RNA undetectable); PT, posttreatment.

Everson GT, et al. AASLD 2012. Oral LB-3 10 Safety, Adverse Events, and Laboratory Abnormalities On Treatment

24-Wk 12-Wk Treatment Treatment Total Number of Patients (%) Group 1, N=16 Group 2, N=16 N = 32 Serious AEs a 0 1 (6) 1 (3) AEs leading to discontinuation 0 0 0 Grade 3–4 AE b 0 1 (6) 1 (3) Grade 3–4 laboratory 0 1 (6) 1 (3) abnormalities c

AE in > 10% of patients in combined treatment groups Headache 4 (25) 6 (38) 10 (31) Diarrhea 2 (13) 6 (38) 8 (25) Asthenia 2 (13) 3 (19) 5 (16) a Renal calculus, considered by the investigator to be unrelated to study therapy. b Grade 3 headache, resolved after 7 days with continued study treatment. c Lymphopenia at a single study visit concomitant with influenza; there were no grade 3–4 bilirubin or transaminase elevations.

Everson GT, et al. AASLD 2012. Oral LB-3 NOT FOR PRODUCT PROMOTIONAL USE 11 BMS in HCV – in Summary

 Daclatasvir – potential first in class and key component of multiple regimens in late stage development

 BMS potentially delivering first all oral therapy in Japan in GT1b patients

 Promising Ph II data recently presented from triple DAA therapy (daclatasvir + asunaprevir + ‘325)

 Lambda is an opportunity in both HCV and HBV

 Partnerships to complement our internal portfolio

NOT FOR PRODUCT PROMOTIONAL USE 12 Credit Suisse Health Care Conference

Doug Manion Senior Vice President, Development Virology, Neuroscience and Japan

November 14, 2012

13